# Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Source: https://onco.cc/trials/nct07523529/  
OnCo record `nct07523529` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine and Cyclophosphamide in advanced solid tumours, run by Beijing Biotech, now recruiting.

## Summary

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07523529 by Beijing Biotech, with 72 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine and Cyclophosphamide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07523529
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Biomarker-Guided Master Protocol Evaluating Autologous Dual-Target CAR-T Cells Selected From a Predefined Target Library in Adults With Advanced Solid Tumors
- Sponsor: Beijing Biotech
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT07523529: https://clinicaltrials.gov/study/NCT07523529

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07523529.json